Fresenius Medical Care AG ADR
FMS: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$37.00 | Pzrfhbs | Bfbt |
Fresenius Medical Care Earnings: Outlook Merely Maintained as Mortality Concerns Reemerge
Narrow-moat Fresenius Medical Care turned in strong second-quarter results but may have disappointed the market with talk of higher mortality rates that cut into treatments, weak cash flows related to the Change network outlook, and a merely maintained 2024 outlook. At first glance, we do not anticipate changing our fair value estimate, which remains well above recent trades.